34987-15-0

Usage

Uses

Used in Organic Synthesis:
5-(Diethylamino)pentylamine is utilized as a reagent in organic synthesis for the preparation of a range of chemical compounds. Its unique structure allows it to participate in various chemical reactions, facilitating the creation of new molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, 5-(Diethylamino)pentylamine serves as a precursor, contributing to the development of new drugs. Its properties make it a valuable component in the synthesis of pharmaceuticals, potentially leading to advancements in medicine.
Used in Surfactant Production:
5-(Diethylamino)pentylamine is employed as an intermediate in the synthesis of surfactants. Surfactants are essential in various industries, including detergents, cosmetics, and industrial cleaning products, due to their ability to reduce surface tension and stabilize emulsions.
Used in Corrosion Inhibitor Synthesis:
5-(Diethylamino)pentylamine is also used in the production of corrosion inhibitors, which are crucial in protecting materials from degradation and extending their service life in various applications, such as in the automotive and aerospace industries.
Used in Polymer, Adhesive, and Coating Industries:
5-(Diethylamino)pentylamine finds application in the manufacturing of polymers, adhesives, and coatings. Its presence in these materials can enhance their properties, such as adhesion, flexibility, and durability.
It is imperative to handle 5-(Diethylamino)pentylamine with caution due to its potential hazards if not managed properly, ensuring safety in its use across different industries.

InChI:InChI=1/C9H22N2/c1-3-11(4-2)9-7-5-6-8-10/h3-10H2,1-2H3/p+2

Upstream product

• 90652-34-9 diethyl-(5-methoxy-pentyl)-amine 
• 6066-93-9 5-diethylaminovaleronitrile 
• 98067-21-1 2-(5-diethylaminopentyl)isoindoline-1,3-dione 
• 954-81-4 N-(5-bromopentyl)phthalimide 
• 1591-16-8 Benzoesaeureester des 1-Cyan-buten-⁽²⁾-ols-⁽¹⁾ 
• 1615-70-9 penta-2,4-dienenitrile 
• 6280-87-1 δ-chlorovaleronitrile 
• 98880-70-7 5-diethylamino-pent-3-enenitrile 

Downstream Products

• 103158-05-0 2,6-diphenyl-isonicotinic acid-(5-diethylamino-pentylamide) 
• 113927-51-8 N,N-diethyl-N'-[7-chloro-1-(2-chloro-benzyl)-1H-[4]quinolylidene]-pentanediyldiamine; dihydrochloride 

Relevant academic research and scientific papers

Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents

The multifaceted nature of Alzheimer's disease (AD) demands treatment with multitarget-directed ligands (MTDLs) to confront the key pathological aberrations. A novel series of triazinoindole derivatives were designed and synthesized. In vitro studies revealed that all the compounds showed moderate to good anticholinesterase activity; the most active compound 23e showed an IC50 value of 0.56 ± 0.02 μM for AChE and an IC50 value of 1.17 ± 0.09 μM for BuChE. These derivatives are also endowed with potent antioxidant activity. To understand the plausible binding mode of the compound 23e, molecular docking studies and molecular dynamics simulation studies were performed, and the results indicated significant interactions of 23e within the active sites of AChE as well as BuChE. Compound 23e successfully diminished H2O2-induced oxidative stress in SH-SY5Y cells and displayed excellent neuroprotective activity against H2O2 as well as Aβ-induced toxicity in SH-SY5Y cells in a concentration dependent manner. Furthermore, it did not show any significant toxicity in neuronal SH-SY5Y cells in the cytotoxicity assay. Compound 23e did not show any acute toxicity in rats at doses up to 2000 mg/kg, and it significantly reversed scopolamine-induced memory deficit in mice model. Additionally, compound 23e showed notable in silico ADMET properties. Taken collectively, these findings project compound 23e as a potential balanced MTDL in the evolution process of novel anti-AD drugs.

Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma

Due to an abundant chondrogenic, poorly vascularized and particularly hypoxic extracellular matrix, chondrosarcoma, a malignant cartilaginous tumour, is chemo- and radio-resistant. Surgical resection with wide margins remains the mainstay of treatment. To address the lack of therapy, our strategy aims to increase anticancer drugs targeting and delivery in the tumour, by leveraging specific chondrosarcoma hallmarks: an extensive cartilaginous extracellular matrix, namely the high negative fixed charge density and severe chronic hypoxia. A dual targeted therapy for chondrosarcoma was investigated by conjugation of a hypoxia-activated prodrug (HAP) to quaternary ammonium (QA) functions which exhibit a high affinity for polyanionic sites of proteoglycans (PGs), the major components of the chondrosarcoma extracellular matrix. Based on preclinical results, an imidazole prodrug, ICF05016, was identified and provided the basis for a lead optimization study. A series of 27 QA-phosphoramide mustard conjugates, differing by the type of QA function and the length of the alkyl linker, was yielded by a common multi-step sequence involving phosphorylation of a key 2-nitroimidazole alcohol. Then, a screening was realized by surface plasmon resonance technology to assess biomolecular interactions between QA derivatives and aggrecan, the most abundant PG in chondrosarcoma. Results revealed that affinity depends more on the type of QA function, than on the linker length. Moreover, the presence of a benzyl group enhanced affinity to aggrecan. Twelve compounds were shortlisted and evaluated for antiproliferative activity (i.e., growth inhibiting concentration 50), under normoxic and hypoxic conditions using the human extraskeletal myeloid chondrosarcoma cell line (HEMC-SS). For all prodrugs, hypoxic selectivity was maintained and even increased, compared with the lead. From this study, compound 31f emerged as the most effective PG-targeted HAPs with a dissociation constant of 2.10 μM in the SPR experiment, a hypoxia cytotoxicity ratio of 24 and an efficient reductive cleavage under chemical and enzymatic conditions.

Regioselective covalent modification of hemoglobin in search of antisickling agents

Although the molecular defect in sickle hemoglobin that produces sickle cell disease has been known for decades, there is still no effective drug treatment that acts on hemoglobin itself. In this work, a series of diversely substituted isothiocyanates (R-NCS) were examined for their regioselective reaction with hemoglobin in an attempt to alter the solubility properties of sickle hemoglobin. Electrospray mass spectrometry, molecular modeling, X-ray crystallography, and conventional protein chemistry were used to study this regioselectivity and the resulting increase in solubility of the modified hemoglobin. Depending on the attached R-group, the isothiocyanates were found to react either with the Cysβ93 or the N-terminal amine of the α-chain. One of the most effective compounds in the series, 2-(N,N-dimethylamino)ethyl isothiocyanate, selectively reacts with the thiol of Cysβ93 which, in conjunction with the cationic group, was seen to perturb the local hemoglobin structure. This modified HbS shows an approximately 30% increase in solubility for the fully deoxygenated state, along with a significant increase in oxygen affinity. This compound and a related analogue appear to readily traverse the erythrocyte membrane. A discussion of the relation of these structural changes to inhibition of gelation is presented. The dual activities of increasing HbS oxygen affinity and directly inhibiting deoxy HbS polymerization, in conjunction with facile membrane traversal, suggest that these cationic isothiocyanates show substantial promise as lead compounds for development of therapeutic agents for sickle cell disease.